Welcome to our dedicated page for Paychex SEC filings (Ticker: PAYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Paychex, Inc. (Nasdaq: PAYX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, drawn from the U.S. Securities and Exchange Commission’s EDGAR system. As a Delaware corporation with shares listed on the Nasdaq Global Select Market, Paychex files a range of documents that give investors and analysts detailed insight into its human capital management (HCM) and payroll services business.
Among the most important filings for PAYX are its annual reports on Form 10-K and quarterly reports on Form 10-Q, which include audited or reviewed financial statements, segment information, discussion of operations, risk factors, and management’s analysis of results. These filings are central for understanding how Paychex generates revenue from cloud-based payroll and HCM software, administrative service organization and professional employer organization offerings, and retirement and insurance-related services, as described in company materials.
Investors will also find current reports on Form 8-K, which Paychex uses to furnish earnings press releases, report on significant corporate events, and provide information about transactions. Recent 8-K filings referenced in the data include results of operations for specific quarters, details of the Paycor HCM, Inc. acquisition, annual meeting voting outcomes, and changes in senior leadership roles.
The definitive proxy statement on Schedule 14A offers additional detail on corporate governance, director elections, executive compensation, and shareholder voting matters. This document can be useful for evaluating Paychex’s governance structure, compensation policies, and shareholder engagement practices.
On Stock Titan, these PAYX filings are updated in near real time as they are posted to EDGAR. AI-powered tools can help summarize lengthy documents such as 10-Ks and 10-Qs, highlight key metrics and disclosures, and surface notable items from 8-Ks, proxy materials, and other submissions. Users researching Paychex’s financial performance, acquisition activity, compensation programs, or governance can use this page as a centralized entry point to the company’s regulatory record, including any insider transaction reports (Form 4) and other relevant SEC forms as they become available.
Paychex (PAYX) reported an insider equity award on a Form 4. A director acquired 725 shares of common stock on 10/15/2025 at $0, noted as an award of restricted stock units subject to vesting under the Amended and Restated 2002 Stock Incentive Plan. Following the transaction, the insider beneficially owned 20,504 shares, held directly.
The filing also lists a new stock option grant for 3,061 shares at an exercise price of $127.52 on 10/15/2025, exercisable 10/15/2026 and expiring 10/14/2035. Additional previously granted options with various strike prices and expirations remain outstanding.
Paychex (PAYX) — Form 4 insider activity: A company director reported equity awards dated 10/15/2025. The filing shows 725 shares of common stock acquired at $0, reflecting settlement of restricted stock units under the Amended and Restated 2002 Stock Incentive Plan. Following this, beneficial ownership stands at 67,364 shares, held directly.
The director also reported a new stock option grant for 3,061 shares at an exercise price of $127.52, granted on 10/15/2025, exercisable starting 10/15/2026 and expiring on 10/14/2035. The filing lists additional previously granted options with exercise prices and expirations on a rolling schedule.
Paychex, Inc. (PAYX) filed a Form 4 showing a director received an equity grant on 10/15/2025. The filing reports the award of 725 restricted stock units at a price of $0, pursuant to the Amended and Restated 2002 Stock Incentive Plan.
The director also received a new stock option for 3,061 shares with an exercise price of $127.52, first exercisable on 10/15/2026 and expiring on 10/14/2035. Following these transactions, the director beneficially owned 2,800 shares directly. The filing also lists previously awarded options, including 5,082 at $120.86 (expiring 07/14/2033), 3,351 at $121.63 (expiring 07/14/2034), and 670 at $140.68 (expiring 07/14/2035).
Paychex (PAYX) Form 4: A director reported equity awards on 10/15/2025. The filing shows an award of 725 shares of common stock at a price of $0, noted as restricted stock units subject to vesting. Following this, 889 shares were beneficially owned directly, and 23,758 shares were beneficially owned indirectly through the Joseph G. Doody Revocable Living Trust. A stock option for 3,061 shares was granted at an exercise price of $127.52, first exercisable on 10/15/2026 and expiring on 10/14/2035.
Paychex (PAYX) reported an insider transaction by its President and CEO. On 10/15/2025, the executive disposed of 624 shares of common stock at $127.52 per share, coded “F”.
According to the footnote, the shares were withheld to satisfy tax obligations arising from the vesting of restricted stock units. Following the transaction, the executive directly holds 81,131 shares of Paychex common stock.
Paychex (PAYX) reported insider activity. A reporting person who is a Director and Chairman received 855 restricted stock units on 10/15/2025 at a price of $0 under the Amended and Restated 2002 Stock Incentive Plan. The person also received a stock option for 3,607 shares with an exercise price of $127.52, first exercisable on 10/15/2026 and expiring on 10/14/2035.
Following these transactions, the filer reported 426,324.3318 shares beneficially owned, held directly. The filing also lists previously granted option awards with various exercise prices and expiration dates.
Paychex (PAYX) reported an insider Form 4 for a company officer (VP, Controller & Treasurer). On 10/15/2025, the officer disposed of 38 shares of common stock at $127.52 under code F, reflecting shares withheld to cover taxes from restricted stock units vesting. Following this transaction, the officer beneficially owns 5,389 shares directly.
The filing also lists outstanding stock options, including 7,310 options at an exercise price of $140.68 (exercisable 07/15/2026; expiration 07/14/2035).
Paychex Inc. (PAYX) director reported equity awards. On 10/15/2025, the insider acquired 725 shares of common stock at $0, described as an award of restricted stock units subject to vesting. Following this, the insider beneficially owned 8,254 shares directly. The filing also shows a new stock option grant for 3,061 shares at an exercise price of $127.52, first exercisable on 10/15/2026 and expiring on 10/14/2035, alongside previously granted options with various terms.
Paychex, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on October 09, 2025 via live webcast. Holders of 322,916,274 shares of common stock were present in person or by proxy.
All ten director nominees were elected to one-year terms. The non-binding advisory vote on named executive officer compensation was approved with 275,491,813 votes for, 10,038,236 against, and 1,115,043 abstentions, with 36,271,182 broker non-votes.
Stockholders also ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026, with 318,217,078 votes for, 4,314,110 against, and 385,086 abstentions.
The Vanguard Group filed Amendment No. 9 to Schedule 13G reporting a passive stake in Paychex, Inc. (PAYX). Vanguard disclosed beneficial ownership of 37,764,731 shares of Paychex common stock, representing 10.5% of the class as of 09/30/2025.
The filing shows 0 shares with sole voting power and 1,925,025 shares with shared voting power. Vanguard reports 34,607,727 shares with sole dispositive power and 3,157,004 shares with shared dispositive power. Vanguard certified the securities were acquired and are held in the ordinary course of business and not to change or influence control.
FAQ
What is the current stock price of Paychex (PAYX)?
What is the market cap of Paychex (PAYX)?
